Prostate Specific Antigen News and Research

RSS

Measuring circulating tumor cells may help better predict prostate cancer survival

New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA).

24 Mar 2014

Bisphenol A may promote prostate tumourigenesis

Bisphenol A, an organic compound that is ubiquitous in plastic products, may have a direct tumourigenic effect in the prostate, US researchers have shown.

17 Mar 2014

Google Glass app helps researchers track spread of diseases around the world

The much-talked-about Google Glass - the eyewear with computer capabilities - could potentially save lives, especially in isolated or far-flung locations, say scientists. They are reporting development of a Google Glass app that takes a picture of a diagnostic test strip and sends the data to computers, which then rapidly beam back a diagnostic report to the user.

3 Mar 2014

New prostate cancer screening method combines existing tests to increase accuracy

Northwestern Medicine- is the first health care provider in the country to offer a new non-invasive blood test for prostate cancer that is nearly three times more accurate than the current standard prostate-specific antigen (PSA) blood test. Known as the Prostate Health Index (phi), the new test's accuracy will effectively remove the need for many men who test positive for elevated PSA levels to undergo a biopsy to achieve a reliable diagnosis.

27 Feb 2014

Serum CRP levels linked to LUTS

Research from Taiwan shows that serum C-reactive protein levels are associated with storage lower urinary tract symptoms and sensory bladder disorders.

3 Feb 2014

Myriad Genetics' Prolaris opens door to a new era of personalized treatment for prostate cancer

Myriad Genetics, Inc. today announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer. Prolaris is a prognostic test that accurately predicts prostate cancer-specific death and metastases and has been validated in 11 clinical studies with more than 5,000 patients.

29 Jan 2014

Nomogram predicts overdiagnosis in prostate cancer screening

US researchers have developed a nomogram which they say can be used to predict whether prostate cancer has been overdiagnosed in individual patients diagnosed following prostate-specific antigen screening.

20 Jan 2014

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding.

16 Jan 2014

Researchers develop personalized tool to predict likelihood of prostate cancer overdiagnosis

Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.

9 Jan 2014

African American men have increased risk of prostate cancer

African American men have an increased risk of prostate cancer and are two times more likely than Caucasian American men to die from the disease. Despite recent questions about the overall usefulness of prostate-specific antigen testing to detect prostate cancer, should PSA screening be used to detect early-stage disease to help save lives in this at-risk population? The controversy is explored in a Review article in Journal of Men's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

7 Jan 2014

Perioperative analgesia may improve prostate cancer outcomes

Neuraxial analgesia added to general anesthesia for radical retropubic prostatectomy may lead to improved oncologic outcomes in prostate cancer, US researchers have found.

6 Jan 2014

Signs of inflammation in man’s prostate biopsy may indicate reduced risk

Signs of inflammation in a man’s prostate biopsy may indicate he has a reduced risk of subsequently being diagnosed with prostate cancer in a future biopsy. That’s the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

9 Dec 2013

C4 Imaging receives FDA clearance for Sirius MRI Marker

C4 Imaging LLC is pleased to announce U.S. Food and Drug Administration 510(k) clearance of its first product, the Sirius™ MRI Marker. The novel Positive-Signal MRI Marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant Magnetic Resonance imaging procedure.

6 Dec 2013

Cancer survival rates still vary widely between European countries

Cancer survival still varies widely between European countries despite major improvements in cancer diagnosis and treatment during the first decade of the 21st century, according to the latest EUROCARE-5 reports covering over 50% of the adult and 77% of the childhood population of Europe.

6 Dec 2013

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The discovery will likely help physicians decide how closely to monitor men potentially at risk for the cancer -- among the most confusing and controversial dilemmas in health care.

4 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

Health insurance coverage does not increase risky behavior

People with health insurance are more likely to use preventive services such as flu shots and health screenings to reduce their risk of serious illness, but they are no more likely than people without health insurance to engage in risky health behaviors such as smoking or gaining weight, researchers at UC Davis and University of Rochester have found.

27 Nov 2013